News
*German researchers have suggested that in elderly patients with early stage Hodgkin's disease, the 4 cycles of ABVD normally planned before radiation were too toxic and not as effective. They suggested up to 20% of patients were unable to complete planned therapy.
They also suggested truncated (AVD) combinations with Revlimid or Brentuximab Vedotin as alternative options.
*Danish researchers have reported that over 400 cases of false alarm mammograms in a screening of 1300 women. They further suggested that in some cases the false alarm rates could reach up to 60% of cases as reported by Medscape. This is very remarkable with possibility to further evaluations including invasive surgical procedures. And a lot of women could end up with an unnecessary Biopsy. And this is bad news because hx of Biopsy increases Breast cancer risk!
Showing posts with label Hodgkin's lymphoma. Show all posts
Showing posts with label Hodgkin's lymphoma. Show all posts
Friday, March 22, 2013
Sunday, January 27, 2013
sCD163 and sTARC are disease response biomarkers for Hodgkin's lymphoma
As published in Clinical Cancer Research,
combined sCD163 and sTARC are better markers of disease response in
patients with Hodgkin's lymphoma undergoing first-line therapy than either
marker alone. sCD163 reflected tumor burden during treatment, while
sTARC was more significant upon completion of therapy.
Subscribe to:
Posts (Atom)